Global CD Antigen Cancer Therapy Market
Global CD Antigen Cancer Therapy Market

CD Antigen Cancer Therapy Comprehensive Study by Type (Monoclonal Antibodies, Antibody-Drug-Conjugates, Tri-Functional & Bi-Specific T-Cell Engager Antibodies, Other), Application (Hospitals, Homecare, Specialty Clinics, Others), Drugs Type (Rituximab, Ocrelizumab, Ofatumumab, Obinutuzumab, Others), Sales Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy), CD Antigens (CD19, CD20, CD22, CD30, CD33, CD37, CD38, CD70, CD137), Administration Route (Intravenous, Subcutaneous, Others) Players and Region - Global Market Outlook to 2025

CD Antigen Cancer Therapy Market Segmented into XX Submarkets. | Forecast Years: 2020- 2025  

Nov 2020 Edition 236 Pages 212 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
What is CD Antigen Cancer Therapy Market?

CD Antigen Cancer Therapy is used to treat cancer diseases. The CD antigens are widely used to targets a variety of cancer therapeutics such as monoclonal antibodies, antibody-drug-conjugates, tri-functional and bi-specific, and among others. These antigens are used to classify white blood cells (WBC) and are especially important for the diagnosis of lymphomas and leukemias. In the 1980s, the first immunotherapy cancer treatment IL-2 was approved by the FDA for the treatment of kidney cancer and melanoma. Since then Various approaches to treat cancer are being continuously being developed. As per the source, in 2019, Canada accounted for approximately 220,400 cancer cases. This increasing number of cancer cases will drive market growth in the coming years.

The market study is being classified by Type (Monoclonal Antibodies, Antibody-Drug-Conjugates, Tri-Functional & Bi-Specific T-Cell Engager Antibodies and Other), by Application (Hospitals, Homecare, Specialty Clinics and Others) and major geographies with country level break-up.

AryoGen Biopharma (Iran), Biocad (Russia), Merck (United States), Sandoz (Germany), UCB (Belgium), Genmab (Denmark), Roche Glycart AG (Switzerland), Biogen Inc. (United States), Celltrion (South Korea), Hetero Drugs Limited (India), mAbxience (Spain), MedImmune (United States) and Genentech (United States) are some of the key players profiled in the study.

The global CD antigen cancer therapy market is highly competitive and consists of a limited number of vendors who compete with each other. The intense competition, changing consumer spending patterns, demographic trends, and frequent changes in consumer preferences pose significant opportunities for the growth of CD antigen cancer therapy providers. Research Analyst at AMA predicts that United States and European Players will contribute to the maximum growth of Global CD Antigen Cancer Therapy market throughout the predicted period.

Segment Analysis
Analyst at AMA have segmented the market study of Global CD Antigen Cancer Therapy market by Type, Application and Region.

On the basis of geography, the market of CD Antigen Cancer Therapy has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). North America region held largest market share in the year 2019. Europe on the other hand stood as second largest market due to the presence of key companies into the region and high technological advancement. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Market Drivers
  • Rising Prevalence Of The Cancer
  • Advancement In The Biotechnological Sector
  • Unmet Medical Need and Large Patient Base in Emerging Economies

Market Trend
  • Emergence of CAR-T Cell Therapy

Restraints
  • High Costs of CD Antigen Cancer Drugs

Opportunities
  • Favorable Reimbursement Schemes for Cancer Therapy
  • Fast-tracked Research & Development by Pharma Companies

Challenges
  • Difficulties in Differentiating CD Target on Cancer Cells





Key Target Audience
New Entrants/Investors, Analysts and Strategic Business Planners, CD Antigen Cancer Therapy Providers, CD Antigen Drug Suppliers, Venture Capitalists and Private Equity Firms, Government Regulatory and Research Organizations and End-Use Industry

Customization in the Report Available:
The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be informed prior purchase
Report Objectives / Segmentation Covered
By Type
  • Monoclonal Antibodies
  • Antibody-Drug-Conjugates
  • Tri-Functional & Bi-Specific T-Cell Engager Antibodies
  • Other
By Application
  • Hospitals
  • Homecare
  • Specialty Clinics
  • Others
By Drugs Type
  • Rituximab
  • Ocrelizumab
  • Ofatumumab
  • Obinutuzumab
  • Others

By Sales Channel
  • Hospital Pharmacy
  • Online Pharmacy
  • Retail Pharmacy

By CD Antigens
  • CD19
  • CD20
  • CD22
  • CD30
  • CD33
  • CD37
  • CD38
  • CD70
  • CD137

By Administration Route
  • Intravenous
  • Subcutaneous
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Rising Prevalence Of The Cancer
      • 3.2.2. Advancement In The Biotechnological Sector
      • 3.2.3. Unmet Medical Need and Large Patient Base in Emerging Economies
    • 3.3. Market Challenges
      • 3.3.1. Difficulties in Differentiating CD Target on Cancer Cells
    • 3.4. Market Trends
      • 3.4.1. Emergence of CAR-T Cell Therapy
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
  • 5. Global CD Antigen Cancer Therapy, by Type, Application, Drugs Type, Sales Channel, CD Antigens, Administration Route and Region (value) (2014-2019)
    • 5.1. Introduction
  • 6. CD Antigen Cancer Therapy: Manufacturers/Players Analysis
    • 6.1. Company Profile
      • 6.1.1. AryoGen Biopharma (Iran)
        • 6.1.1.1. Business Overview
        • 6.1.1.2. Products/Services Offerings
        • 6.1.1.3. Financial Analysis
        • 6.1.1.4. SWOT Analysis
      • 6.1.2. Biocad (Russia)
        • 6.1.2.1. Business Overview
        • 6.1.2.2. Products/Services Offerings
        • 6.1.2.3. Financial Analysis
        • 6.1.2.4. SWOT Analysis
      • 6.1.3. Merck (United States)
        • 6.1.3.1. Business Overview
        • 6.1.3.2. Products/Services Offerings
        • 6.1.3.3. Financial Analysis
        • 6.1.3.4. SWOT Analysis
      • 6.1.4. Sandoz (Germany)
        • 6.1.4.1. Business Overview
        • 6.1.4.2. Products/Services Offerings
        • 6.1.4.3. Financial Analysis
        • 6.1.4.4. SWOT Analysis
      • 6.1.5. UCB (Belgium)
        • 6.1.5.1. Business Overview
        • 6.1.5.2. Products/Services Offerings
        • 6.1.5.3. Financial Analysis
        • 6.1.5.4. SWOT Analysis
      • 6.1.6. Genmab (Denmark)
        • 6.1.6.1. Business Overview
        • 6.1.6.2. Products/Services Offerings
        • 6.1.6.3. Financial Analysis
        • 6.1.6.4. SWOT Analysis
      • 6.1.7. Roche Glycart AG (Switzerland)
        • 6.1.7.1. Business Overview
        • 6.1.7.2. Products/Services Offerings
        • 6.1.7.3. Financial Analysis
        • 6.1.7.4. SWOT Analysis
      • 6.1.8. Biogen Inc. (United States)
        • 6.1.8.1. Business Overview
        • 6.1.8.2. Products/Services Offerings
        • 6.1.8.3. Financial Analysis
        • 6.1.8.4. SWOT Analysis
      • 6.1.9. Celltrion (South Korea)
        • 6.1.9.1. Business Overview
        • 6.1.9.2. Products/Services Offerings
        • 6.1.9.3. Financial Analysis
        • 6.1.9.4. SWOT Analysis
      • 6.1.10. Hetero Drugs Limited (India)
        • 6.1.10.1. Business Overview
        • 6.1.10.2. Products/Services Offerings
        • 6.1.10.3. Financial Analysis
        • 6.1.10.4. SWOT Analysis
      • 6.1.11. MAbxience (Spain)
        • 6.1.11.1. Business Overview
        • 6.1.11.2. Products/Services Offerings
        • 6.1.11.3. Financial Analysis
        • 6.1.11.4. SWOT Analysis
      • 6.1.12. MedImmune (United States)
        • 6.1.12.1. Business Overview
        • 6.1.12.2. Products/Services Offerings
        • 6.1.12.3. Financial Analysis
        • 6.1.12.4. SWOT Analysis
      • 6.1.13. Genentech (United States)
        • 6.1.13.1. Business Overview
        • 6.1.13.2. Products/Services Offerings
        • 6.1.13.3. Financial Analysis
        • 6.1.13.4. SWOT Analysis
  • 7. Global CD Antigen Cancer Therapy Sale, by Type, Application, Drugs Type, Sales Channel, CD Antigens, Administration Route and Region (value) (2020-2025)
    • 7.1. Introduction
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Company Basic Information, Sales Area and Its Competitors
  • Table 2. Company Basic Information, Sales Area and Its Competitors
  • Table 3. Company Basic Information, Sales Area and Its Competitors
  • Table 4. Company Basic Information, Sales Area and Its Competitors
  • Table 5. Company Basic Information, Sales Area and Its Competitors
  • Table 6. Company Basic Information, Sales Area and Its Competitors
  • Table 7. Company Basic Information, Sales Area and Its Competitors
  • Table 8. Company Basic Information, Sales Area and Its Competitors
  • Table 9. Company Basic Information, Sales Area and Its Competitors
  • Table 10. Company Basic Information, Sales Area and Its Competitors
  • Table 11. Company Basic Information, Sales Area and Its Competitors
  • Table 12. Company Basic Information, Sales Area and Its Competitors
  • Table 13. Company Basic Information, Sales Area and Its Competitors
  • Table 14. Research Programs/Design for This Report
  • Table 15. Key Data Information from Secondary Sources
  • Table 16. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. AryoGen Biopharma (Iran) Revenue, Net Income and Gross profit
  • Figure 5. AryoGen Biopharma (Iran) Revenue: by Geography 2019
  • Figure 6. Biocad (Russia) Revenue, Net Income and Gross profit
  • Figure 7. Biocad (Russia) Revenue: by Geography 2019
  • Figure 8. Merck (United States) Revenue, Net Income and Gross profit
  • Figure 9. Merck (United States) Revenue: by Geography 2019
  • Figure 10. Sandoz (Germany) Revenue, Net Income and Gross profit
  • Figure 11. Sandoz (Germany) Revenue: by Geography 2019
  • Figure 12. UCB (Belgium) Revenue, Net Income and Gross profit
  • Figure 13. UCB (Belgium) Revenue: by Geography 2019
  • Figure 14. Genmab (Denmark) Revenue, Net Income and Gross profit
  • Figure 15. Genmab (Denmark) Revenue: by Geography 2019
  • Figure 16. Roche Glycart AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 17. Roche Glycart AG (Switzerland) Revenue: by Geography 2019
  • Figure 18. Biogen Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 19. Biogen Inc. (United States) Revenue: by Geography 2019
  • Figure 20. Celltrion (South Korea) Revenue, Net Income and Gross profit
  • Figure 21. Celltrion (South Korea) Revenue: by Geography 2019
  • Figure 22. Hetero Drugs Limited (India) Revenue, Net Income and Gross profit
  • Figure 23. Hetero Drugs Limited (India) Revenue: by Geography 2019
  • Figure 24. MAbxience (Spain) Revenue, Net Income and Gross profit
  • Figure 25. MAbxience (Spain) Revenue: by Geography 2019
  • Figure 26. MedImmune (United States) Revenue, Net Income and Gross profit
  • Figure 27. MedImmune (United States) Revenue: by Geography 2019
  • Figure 28. Genentech (United States) Revenue, Net Income and Gross profit
  • Figure 29. Genentech (United States) Revenue: by Geography 2019
Some of the key companies/manufacturers profiled in the report
  • AryoGen Biopharma (Iran)
  • Biocad (Russia)
  • Merck (United States)
  • Sandoz (Germany)
  • UCB (Belgium)
  • Genmab (Denmark)
  • Roche Glycart AG (Switzerland)
  • Biogen Inc. (United States)
  • Celltrion (South Korea)
  • Hetero Drugs Limited (India)
  • mAbxience (Spain)
  • MedImmune (United States)
  • Genentech (United States)
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation